论文部分内容阅读
目的分析欣维宁联合药物支架在急性心肌梗塞(AMI)中的应用价值。方法将78例AMI行PCI治疗的患者分成观察组和对照组,观察组植入药物洗脱支架并加用欣维宁,对照组仅植入药物洗脱支架,对比分析两组患者的TIMI、心肌再灌注MBG分级、ST段回落情况、各项心功能指标以及心脏事件发生率。结果观察组术后心肌再灌注MBG分级、术后1周ST段完全回落、各项心功能指标明显好于对照组,差异均具有统计学意义(P<0.05),观察组心脏事件发生率低于对照组(7.5%Vs 23.7%),差异具有统计学意义(P<0.05)。结论欣维宁联合药物支架治疗AMI可使心肌缺血再灌注,减少无复流现象、降低心脏事件的发生率,可明显改善患者的心功能及预后。
Objective To analyze the value of combination of Hinfenin and drug-eluting stent in acute myocardial infarction (AMI). Methods Seventy-eight patients undergoing PCI with AMI were divided into observation group and control group. The observation group was implanted with drug-eluting stent plus xvvinine. The control group was only implanted with drug-eluting stent. The TIMI, Myocardial reperfusion MBG classification, ST segment regression, the various cardiac function indicators and the incidence of cardiac events. Results The postoperative myocardial reperfusion MBG grade was observed in the observation group. The ST segment of the observation group was completely retreated at 1 week after operation. The cardiac function indexes were significantly better in the observation group than those in the control group (P <0.05). The incidence of cardiac events in the observation group was lower In the control group (7.5% Vs 23.7%), the difference was statistically significant (P <0.05). Conclusion Shenweining combined with drug-eluting stent can improve myocardial ischemia and reperfusion, reduce the phenomenon of no-reflow, reduce the incidence of cardiac events and improve cardiac function and prognosis.